Title: Treatment of non-small cell lung cancer with EGFR-TKI
Abstract:Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the key to the treatment of advanced non-small cell lung cancer (NSCLC), but there are various drug-resistant mutations in t...Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the key to the treatment of advanced non-small cell lung cancer (NSCLC), but there are various drug-resistant mutations in the latter stage. The first and second generation of EGFR-TKIs significantly prolong the survival of patients with EGFR-activated mutant tumors. The third generation of EGFR-TKIs effectively inhibit the progress of T790M mutant tumors. The fourth generation of EGFR-TKIs inhibit both L858R, T790M and L858R, T790M, C797S mutant tumors. Using circulating tumor DNA and exogenous RNA can effectively detect the mutation types of EGFR, and choose EGFR-TKIs therapy or combined chemotherapy according to the mutation types.
Key words:
Carcinoma, non-small-cell lung; Receptor, epidermal growth factor; Molecular targeted therapy; Epidermal growth factor receptor-tyrosine kinase inhibitors; Drug resistanceRead More
Publication Year: 2019
Publication Date: 2019-02-08
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot